How to buy Neoleukin Therapeutics stock | $10.03

Neoleukin Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Neoleukin Therapeutics shares (NLTX) are listed on the NASDAQ and all prices are listed in US Dollars. Neoleukin Therapeutics employs 78 staff and has a market cap (total outstanding shares value) of 0.00.

Neoleukin Therapeutics stock price (NASDAQ: NLTX)

Use our graph to track the performance of NLTX stocks over time.

Neoleukin Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-31.

Latest market close	$10.03
52-week range	$6.92 - $17.95
50-day moving average	$9.14
200-day moving average	$11.30
Wall St. target price	$20.40
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.94

Buy Neoleukin Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Neoleukin Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Neoleukin Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Neoleukin Therapeutics price performance over time

Historical closes compared with the close of $10.03 from 2021-05-28

1 week (2021-07-24)	N/A
1 month (2021-07-02)	4.48%
3 months (2021-05-04)	-11.40%
6 months (2021-01-31)	N/A

1 year (2020-07-31)	N/A
2 years (2019-07-31)	N/A
3 years (2018-07-31)	N/A
5 years (2016-07-31)	N/A

Neoleukin Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-16.79%
Return on equity TTM	-25.05%
Profit margin	0%
Book value	$4.23
Market capitalisation	$296 million

TTM: trailing 12 months

Shorting Neoleukin Therapeutics shares

There are currently 2.1 million Neoleukin Therapeutics shares held short by investors – that's known as Neoleukin Therapeutics's "short interest". This figure is 0.1% up from 2.1 million last month.

There are a few different ways that this level of interest in shorting Neoleukin Therapeutics shares can be evaluated.

Neoleukin Therapeutics's "short interest ratio" (SIR)

Neoleukin Therapeutics's "short interest ratio" (SIR) is the quantity of Neoleukin Therapeutics shares currently shorted divided by the average quantity of Neoleukin Therapeutics shares traded daily (recently around 207564.91935484). Neoleukin Therapeutics's SIR currently stands at 9.92. In other words for every 100,000 Neoleukin Therapeutics shares traded daily on the market, roughly 9920 shares are currently held short.

However Neoleukin Therapeutics's short interest can also be evaluated against the total number of Neoleukin Therapeutics shares, or, against the total number of tradable Neoleukin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neoleukin Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Neoleukin Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0949% of the tradable shares (for every 100,000 tradable Neoleukin Therapeutics shares, roughly 95 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Neoleukin Therapeutics.

Find out more about how you can short Neoleukin Therapeutics stock.

Neoleukin Therapeutics share dividends

We're not expecting Neoleukin Therapeutics to pay a dividend over the next 12 months.

Neoleukin Therapeutics share price volatility

Over the last 12 months, Neoleukin Therapeutics's shares have ranged in value from as little as $6.92 up to $17.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neoleukin Therapeutics's is 0.9744. This would suggest that Neoleukin Therapeutics's shares are less volatile than average (for this exchange).

Neoleukin Therapeutics overview

Neoleukin Therapeutics, Inc. , a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc.

Frequently asked questions

What percentage of Neoleukin Therapeutics is owned by insiders or institutions?
Currently 22.339% of Neoleukin Therapeutics shares are held by insiders and 68.194% by institutions. How many people work for Neoleukin Therapeutics?
Latest data suggests 78 work at Neoleukin Therapeutics. When does the fiscal year end for Neoleukin Therapeutics?
Neoleukin Therapeutics's fiscal year ends in December. Where is Neoleukin Therapeutics based?
Neoleukin Therapeutics's address is: 1616 Eastlake Avenue East, Seattle, WA, United States, 98102 What is Neoleukin Therapeutics's ISIN number?
Neoleukin Therapeutics's international securities identification number is: US64049K1043 What is Neoleukin Therapeutics's CUSIP number?
Neoleukin Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03842B101